Skip to main
CRDL

Cardiol Therapeutics (CRDL) Stock Forecast & Price Target

Cardiol Therapeutics (CRDL) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cardiol Therapeutics is a promising late-stage life sciences company with a focus on developing innovative therapies for heart disease. The company's primary small-molecule candidate, CardiolRx, has shown promising results in suppressing disease activity in clinical studies, with a low recurrence rate after withdrawal. The company's plans for expanding enrollment in its MAVERIC trial and the encouraging read-through from other withdrawal trials suggest a potential for long-term success and a strong outlook for the company's stock.

Bears say

Cardiol Therapeutics is developing anti-inflammatory and anti-fibrotic therapies for heart disease, but with a negative outlook. The MAVERIC studies have shown a lower-than-expected recurrence rate, but the company has increased the enrollment criteria to potentially mitigate the risk. Peer-reviewed Phase II data have provided support for the potential of CardiolRx as an oral treatment for recurrent pericarditis, but the market continues to underappreciate its potential. However, we believe the ongoing MAVERIC trial and published data strengthen the clinical rationale and present a favorable risk-reward for the company.

Cardiol Therapeutics (CRDL) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cardiol Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cardiol Therapeutics (CRDL) Forecast

Analysts have given Cardiol Therapeutics (CRDL) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Cardiol Therapeutics (CRDL) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cardiol Therapeutics (CRDL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.